Developing G-quartet oligonucleotides as novel anti-HIV agents: Focus on anti-HIV drug design

Expert Opinion on Investigational Drugs

Volumn 9, Issue 8, 2000, Pages 1777-1785

  Jing, N ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

HIV; Human immunodeficiency virus type 1 integrase

Indexed keywords

AMINO ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CATION; CD4 ANTIGEN; GUANINE; INTEGRASE; INTEGRASE INHIBITOR; ISIS 5320; NEW DRUG; OLIGONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; T 30695; T 40125; T 40216; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENZYME; VIRUS RNA; ZINTEVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENTIATION; DRUG STABILITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MOUSE; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

EID: 0033900170     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.8.1777     Document Type: Review

References (52)

1. Current concepts in antisense drug design
2. The design of antisense RNA
3. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections
4. Antisense oligonucleotides as therapeutic agents
5. Recruitment of transcription factors to the target site by triplex-forming oligonucleotides
6. Accessibility of nuclear DNA to triplex-forming oligonucleotides: The integrated HIV-1 provirus as a target
7. Inhibition of HIV-1 replication by a two-strand system (FTFOs) targeted to the polypurine tract
8. Combinatorially selected guanosine-quartet structure is a potent inhibitor of HIV envelope-mediated cell fusion
9. Suppression of human immunodeficiency virus Type 1 activity in vitro by oligonucleotides which form intramolecular tetrads
10. Ion selective folding of loop domains in a potent anti-HIV oligonucleotide
11. Inhibition of the human immunodeficiency virus Type 1 integrase by guanosine quartet structures
12. Stability-activity relationships of a family of G-tetrad forming oligonucleotides as potent HIV inhibitors
13. Helix formation by guanylic acid
14. G-quartet structures in telomeric DNA
15. Multistranded DNA structures
16. Telomere DNA structure
17. Telomere structure and function
18. The thermodynamics of DNA structures that contain lesions or guanine tetrads
19. Following G-quartet formation by UV-spectroscopy
20. A sodium-potassium switch in the formation of four-stranded G4-DNA
21. Effect of thymine tract length on the structure and stability of model telomeric sequences
22. Potent and specific inhibition of HIV envelop-mediated cell fusion and virus binding by G-quartet-forming oligonucleotide (ISIS 5320)
23. Inhibition of human immunodeficiency virus Type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320
24. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus Type 1
25. Acute, multiple-dose and genetic toxicology of AR177, an anti-HIV oligonucleotide
26. Potassium-induced loop conformation transition of a potent anti-HIV oligonucleotide
27. Structure-activity of tetradforming oligonucleotides as a potent anti-HIV therapeutic drug
28. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir)
29. The retroviral enzymes
30. HIV-1 integrase: Structure organization, conformational changes and catalysis
31. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
32. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
33. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
34. Domains of integrase protein of human immunodeficiency virus type-1 responsible for polynucleotidyl transfer and zinc binding
35. Biophysical and enzymatic properties of the catalytic domain of HIV-1 integrase
36. Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases
37. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium
38. Critical contacts between HIV-1 integrase and viral DNA identified by structure-based analysis and photo-crosslinking
39. Identification of a nucleotide binding site in HIV-1 integrase
40. A soluble active mutant of HIV-1 integrase: Involvement of both the core and carboxyl-terminal domains in multimerization
41. Structure implication of spectroscopic characterization of a putative zinc fingerpeptide from HIV-1 integrase
42. Characterization of the DNA-binding activity of HIV-1 integrase using a filter binding assay
43. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization and enhances catalytic activity
44. Identification of the catalytic and DNA-binding region of the human immunodeficiency virus Type 1 integrase protein
45. The core and carboxyl-terminal domain of the integrase protein of human immunodeficiency virus Type 1 each contribute to non-specific DNA binding
46. Characterization of a DNA binding domain in the C-terminus of HIV-1 integrase by deletion mutagenesis
47. Solution structure of the DNA binding domain of HIV-1 integrase
48. The DNA-binding domain of HIV-1 integrase has an SH3-like fold
49. Inhibitors of human immunodeficiency virus integrase
50. Mechanism of inhibition of HIV-1 integrase by G-tetrad forming oligonucleotides
51. Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide
52. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus Type 1